Copertina

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jianrong Li, Dalong Yang, Jianhong Zhong, Yingyang Liao
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
di: Na‐Ling Kang, et al.
Pubblicazione: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
di: Jing Li, et al.
Pubblicazione: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
di: WenXian OuYang, et al.
Pubblicazione: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
di: Chen‐Pi Li, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
di: Lisa Sandmann, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
di: Maria Buti, et al.
Pubblicazione: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
di: Hye Won Lee, et al.
Pubblicazione: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
di: Eiichi Ogawa
Pubblicazione: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
di: Jung Eun Park, et al.
Pubblicazione: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
di: Yen‐Chun Liu, et al.
Pubblicazione: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
di: Lukas Hartl, et al.
Pubblicazione: (2024)

Editorial: Can dietary gluten restriction improve hepatic steatosis?
di: Hariklia Kranidioti, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
di: Elena Vargas‐Accarino, et al.
Pubblicazione: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
di: Philip Vutien, et al.
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis
di: Carolyn Singleton, et al.
Pubblicazione: (2024)

Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C
di: Nikolaos Papadopoulos, et al.
Pubblicazione: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
di: Matthew J. Townsend, et al.
Pubblicazione: (2024)

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
di: Julian Hercun, et al.
Pubblicazione: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
di: Vishnu Girish, et al.
Pubblicazione: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
di: Ann T. Ma, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
di: Basile Njei, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
di: Eunice X. X. Tan, et al.
Pubblicazione: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling
di: Eunice X. Tan, et al.
Pubblicazione: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
di: Nina Dominik, et al.
Pubblicazione: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
di: Richie Manikat, et al.
Pubblicazione: (2024)

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints
di: Philippe Sultanik, et al.
Pubblicazione: (2024)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
di: Ze‐Hua Zhao, et al.
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply
di: Sara Ellegaard Paaske, et al.
Pubblicazione: (2026)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?
di: Richard Kozarek
Pubblicazione: (2024)